Skip to main content
CADL logo

Candel Therapeutics, Inc. (CADL)

CADLNASDAQHealthcareBiotechnology

$5.04Today:−$0.19 (−3.57%)1Y +12.75%

As of Nov 20, 2026 close

Market cap
$396.99M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$4.35$14.00
Volume (live)
-
Avg. volume (3M)
1.44M

Candel Therapeutics (CADL) Income Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Candel Therapeutics posted a net loss of $38.18M, compared with a net loss of $55.18M a year earlier.

Candel Therapeutics Income Statement Analysis

Values in millions USD

Scroll to see more
Candel Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period endingSep 2026Dec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Revenue & Gross Profit
Revenue-0.000.000.000.130.130.130.13
Cost of Revenue-0.000.0023.5920.3514.590.000.00
Gross Profit-0.000.00-23.59-20.22-14.470.130.13
Operating Expenses
Research & Development56.0529.7619.3123.5920.7915.187.946.61
Selling, General & Administrative25.7118.4214.0614.4114.5011.265.992.56
Operating Expenses81.6948.1833.3738.0014.5011.2613.949.16
Operating Income-81.69-48.18-33.37-38.00-34.72-25.73-13.81-9.04
Other Income/Expense
Interest Income5.913.921.092.081.220.000.111.07
Interest Expense6.152.122.09-2.60-1.71-0.050.000.00
Other Income/Expense-17.5210.08-20.800.4515.93-10.40-3.980.80
Income
Income Before Tax-99.14-38.18-55.18-37.94-18.79-36.12-17.68-8.24
Income Tax Expense-0.000.000.000.000.000.000.00
Net Income-99.14-38.18-55.18-37.94-18.79-36.12-17.68-8.24
Net Income - Continuous Operations-99.14-38.18-55.18-37.94-18.79-36.12-17.68-8.24
Net Income - Discontinued Operations--------
EBITDA-80.00-47.33-52.10-37.04-33.94-25.49-13.72-8.42
EBIT-80.65-48.18-53.09-38.00-34.72-25.73-13.81-
Depreciation & Amortization0.650.850.990.960.780.230.090.04
Earnings Per Share
Basic EPS-1.48-0.72-1.74-1.31-0.65-1.91-2.00-
Diluted EPS-1.48-0.72-1.74-1.31-0.65-1.91-2.00-
Basic Shares Outstanding67.1952.9631.6828.9428.8218.8711.6218.71
Diluted Shares Outstanding67.1952.9631.6828.9428.8218.8711.6218.71

Source: Company financial statements from annual and quarterly filings. Data as of Sep 30, 2026. Data sources and methodology

Frequently Asked Questions About Candel Therapeutics Financial Statements

Is Candel Therapeutics profitable?

No. Candel Therapeutics reported a net loss of $38.18M in fiscal 2025. In fiscal 2024 it lost $55.18M.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition